- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00793221
Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent (CIBELES)
Randomized Comparison Between Sirolimus-eluting and Everolimus-eluting Coronary Stents in Chronic Coronary Occlusions
Chronic total coronary occlusions (CTO) have an especially high risk of angiographic restenosis, and need for new revascularization procedures. Drug-eluting coronary stents (DES) have demonstrated to significantly reduce the risk of restenosis and new revascularization procedures in comparison with bare-metal stents.
Most data on the efficacy of DES come from the sirolimus-eluting coronary stent Cypher (Cordis corp.), and paclitaxel-eluting coronary stent Taxus (Boston Sci.), and the Cypher stent is the only DES that has been randomly tested in CTO. Among second-generation DES, everolimus-eluting stent (EES) has shown excellent angiographic and clinical results, but this DES has not been studied in unfavourable scenario (such as CTO).
The aim of the CIBELES trial is to demonstrate the hypothesis that EES are equally effective in comparison with sirolimus-eluting stents in the treatment of CTO, in terms of angiographic efficacy considered as in-stent late lumen loss.
Studieoversigt
Status
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients ≥ 18 year-old.
- A total occlusion (TIMI 0-1) with an estimated time of occlusion > 2 weeks.
- Symptomatic or silent ischaemia, or viable myocardium.
- The occlusion is suitable for percutaneous coronary intervention.
- The guidewire has crossed the occlusion, and the occlusion has been dilated with balloon or other device.
Exclusion Criteria:
- Acute myocardial infarction in the myocardial area supplied by the target vessel within 2 weeks before the inclusion in the study.
- The lesion can not be crossed with the guidewire and balloon angioplasty.
- The vessel has been previously treated percutaneously.
- The lesion is not suitable for a 2.25-3.5 coronary stent implantation.
- The patient is not willing to undergo an angiographic follow-up.
- The patient has contraindications for prolonged double (aspirin plus clopidogrel) anti-platelet therapy (e.g. allergy to aspirin, need for chronic oral anti-coagulation, or scheduled surgical intervention within 12 months.
- Pregnancy or absence of pregnancy test in women of childbearing age.
- Chronic renal failure (creatinine plasmatic values > 3.0 mg/dl).
- Plasmatic platelet count < 100.000 mm-3 or > 700.000 mm-3.
- The patient has a severe non-cardiac disease that limits his/her life expectancy to < 1 year.
- The patient is currently included in other randomized trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: Sirolimus-eluting stent
Implantation of sirolimus-eluting coronary stent
|
Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
|
Aktiv komparator: Everolimus-eluting stent
Implantation of everolimus-eluting coronary stent
|
Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
In-stent late lumen loss at 9-month angiographic follow-up
Tidsramme: 9 months
|
9 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Angiographic: rate of binary angiographic restenosis, rate of vessel re-occlusion, and in-segment late loss, at 9 months
Tidsramme: 9 and 12 months
|
9 and 12 months
|
Clinical: death, myocardial infarction, new revascularization, and angina status at 1 year.
Tidsramme: 9 and 12 months
|
9 and 12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Ruiz-Garcia J, Teles R, Rumoroso JR, Cyrne Carvalho H, Goicolea FJ, Moreu J, Mauri J, Mainar V, Garcia E, Moreno R; CIBELES investigators. Comparison between diabetic and non-diabetic patients after successful percutaneous coronary intervention for chronic total occlusions in the drug-eluting stent era. Rev Port Cardiol. 2015 Apr;34(4):263-70. doi: 10.1016/j.repc.2014.10.009. Epub 2015 Apr 1.
- Moreno R, Garcia E, Teles R, Rumoroso JR, Cyrne Carvalho H, Goicolea FJ, Moreu J, Mauri J, Sabate M, Mainar V, Patricio L, Valdes M, Fernandez Vazquez F, Sanchez-Recalde A, Galeote G, Jimenez-Valero S, Almeida M, Lopez de Sa E, Calvo L, Plaza I, Lopez-Sendon JL, Martin JL; CIBELES Investigators. Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial. Circ Cardiovasc Interv. 2013 Feb;6(1):21-8. doi: 10.1161/CIRCINTERVENTIONS.112.000076. Epub 2013 Feb 12.
- Moreno R, Garcia E, Teles RC, Almeida MS, Carvalho HC, Sabate M, Martin-Reyes R, Rumoroso JR, Galeote G, Goicolea FJ, Moreu J, Mainar V, Mauri J, Ferreira R, Valdes M, Perez de Prado A, Martin-Yuste V, Jimenez-Valero S, Sanchez-Recalde A, Calvo L, Lopez de Sa E, Macaya C, Lopez-Sendon JL. A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial. EuroIntervention. 2010 May;6(1):112-6.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjertesygdomme
- Hjerte-kar-sygdomme
- Karsygdomme
- Åreforkalkning
- Arterielle okklusive sygdomme
- Koronararteriesygdom
- Myokardieiskæmi
- Koronar sygdom
- Koronar okklusion
- Lægemidlers fysiologiske virkninger
- Anti-infektionsmidler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antibakterielle midler
- Antibiotika, antineoplastisk
- Antifungale midler
- Everolimus
- Sirolimus
Andre undersøgelses-id-numre
- CIBELES (Anden identifikator: Alias Study Number)
- HHLP003
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Koronararteriesygdom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aorta origin of the coronary artery (AAOCA)Italien
-
University Hospital OstravaRekrutteringIn-Stent Carotis Artery RestenosisTjekkiet
-
Sohag UniversityIkke rekrutterer endnuUmblical artery Doppler under terminsgraviditetEgypten
-
Inova Health Care ServicesBoston Scientific CorporationAfsluttetKoronar angiografi | Transradial adgang | Radial arterie Intimal Medial Tykkelse | Distal Radial Artery Access (dTRA)Forenede Stater
-
Baylor College of MedicineAfsluttetLungeblødning | MAPCA - Major Aortopulmonary Collateral ArteryForenede Stater
-
Daewoong Pharmaceutical Co. LTD.UkendtMCA - Middle Cerebral Artery DissektionKorea, Republikken
-
Resicardunion nationale de formation et d'evaluation en medecine cardio-vasculaireAfsluttetHjertefejl | Akut koronarsyndrom | Koronar bypass-graft Stenose af Native Artery GraftFrankrig
-
AldagenUkendtSlag | Iskæmisk slagtilfælde | Slagtilfælde i Middle Cerebral Artery (MCA)Forenede Stater
Kliniske forsøg med Implantation of sirolimus-eluting coronary stent
-
Genoss Co., Ltd.RekrutteringKoronararteriesygdom | Stent til eluering af lægemidlerKorea, Republikken
-
Concept Medical Inc.Aktiv, ikke rekrutterendeKoronararteriesygdom | Diabetes | Akut koronarsyndromSchweiz, Australien, Korea, Republikken, Frankrig, Belgien, Holland, Det Forenede Kongerige, Indien, Østrig, Bangladesh, Brasilien, Tjekkiet, Tyskland, Irland, Italien, Malaysia, Mexico, Polen, Singapore, Sverige, Taiwan
-
Meril Life Sciences Pvt. Ltd.Ukendt
-
Scitech Produtos Medicos LtdaUkendtKoronararteriesygdom | BifurkationslæsionBrasilien
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat...Afsluttet
-
Herz-Zentrums Bad KrozingenAfsluttetArterielle okklusive sygdommeTyskland
-
Charite University, Berlin, GermanyTechniker KrankenkasseAfsluttetKoronararteriesygdomTyskland
-
Meril Life Sciences Pvt. Ltd.UkendtHjertekrampeJordan, Ungarn, Malaysia, Holland
-
Biotronik AGAfsluttetRestenoser, koronar | de Novo | Symptomatisk iskæmisk hjertesygdomBrasilien
-
Meril Life Sciences Pvt. Ltd.Ikke rekrutterer endnu